Jennifer Fulk, Chief Financial Officer of Kura Oncology, Inc. (NASDAQ:KURA), filed a Form 4 on September 10, 2026, reporting the acquisition of stock options covering 450,000 shares of common stock, with a transaction date of September 8, 2026.

Key Highlights

  • Option grant: Jennifer Fulk acquired options to purchase 450,000 shares of Kura Oncology common stock on September 8, 2026.
  • Exercise price: The options carry an exercise price of $12.52 per share.
  • Expiration date: The options expire on September 7, 2036.
  • Vesting schedule: One-quarter of the shares vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting in 1/48th monthly installments over 36 months thereafter.
  • Price paid: The derivative securities were acquired at a price of $0.00.
  • Ownership form: The options are held directly by the reporting person.
  • Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

CFO Jennifer Fulk's Option Grant Details at Kura Oncology

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Jennifer Fulk, serving as Chief Financial Officer of Kura Oncology, Inc. (NASDAQ:KURA), acquired derivative securities in the form of options to purchase common stock. The transaction was dated September 8, 2026, and the filing was submitted on September 10, 2026, by Teresa Bair as attorney-in-fact for Jennifer Fulk.

The filing reports that 450,000 options were acquired (transaction code "A") with an exercise price of $12.52 per share and an expiration date of September 7, 2036. The price of the derivative security at acquisition is listed as $0.00. Following the reported transaction, the total number of derivative securities beneficially owned by Fulk in this option series stands at 450,000, held directly.

As described in the filing's explanation of responses, the vesting schedule provides that one-quarter of the shares vest on the one-year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. The filing also indicates, via a checked box, that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

The filing discloses that Kura Oncology CFO Jennifer Fulk received options to purchase 450,000 shares of common stock at $12.52 per share, expiring September 7, 2036, under a standard four-year vesting schedule, acquired at no cost and held directly.